I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter @theroberthart or email me at [email protected]
Regeneron’s Covid-19 antibody therapy is capable of slashing death rates among hospitalized patients who do not have a natural immune response against the virus, according to preliminary findings from a U.K. study that could change how it is used in practice and revitalize interest in antiviral treatments to help those who have contracted the disease.
The trial marks the first time an antiviral treatment for Covid-19—which targets the virus and not the body—has been demonstrated to reduce the risk of death in hospitalized patients. it would immediately make use of the data to try and expand its existing emergency use authorization in the U.S., where it is used for outpatients at risk of developing severe disease.
The treatment offered no benefit for patients who had mounted a natural antibody response, which researchers said could help easily direct the therapy to those who need it most. this finding, saying it will allow providers to prioritize treatment to those patients who can benefit from the therapy.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Regeneron’s Antibody Drug Cuts Risk of Death in Some Covid-19 PatientsRegeneron’s antibody treatment has been shown to significantly cut the risk of death among some hospitalized Covid-19 patients
Read more »
A third dose of Covid vaccine may help protect immunocompromised patients, small study suggestsA third dose of a Covid-19 vaccine may boost protection for some people with weakened immune systems, study suggests.
Read more »
AstraZeneca’s Covid-19 Antibody Treatment Failed To Prevent Symptoms In Exposed IndividualsThe monoclonal antibody treatment reduced the risk of developing symptomatic Covid-19 by a statistically insignificant 33% among unvaccinated adults.
Read more »
Novavax: Large study finds COVID-19 shot about 90% effectiveVaccine maker Novavax said Monday its COVID-19 shot was highly effective against the disease and also protected against variants in a large study in the U.S. and Mexico, potentially offering the world yet another weapon against the virus at a time when developing countries are desperate for doses. While demand for COVID-19 shots in the U.S. has dropped off dramatically and the country has more than enough doses to go around, the need for more vaccines around the world remains critical. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting supplies in poor parts of the world.
Read more »
A life-saving new drug for covid-19 is foundBut only rich countries will benefit, and even they will struggle to get hold of it | Science & technology
Read more »
Extra COVID-19 vaccine may help protect transplant patientsA small study offers a hint that an extra dose of COVID-19 vaccine might give organ transplant recipients a boost in protection.
Read more »